tions. Those conditions include dermatological diseases such as dermatitis herpetiformis and PV [7] . Although dapsone has been used in the treatment of pemphigus for many years, most of our knowledge concerning its efficacy is based on studies involving only a very small number of patients [6] . Therefore, the aim of this retrospective case series was to report our experience with dapsone as an adjuvant to systemic steroids in the treatment of PV.
Materials and Methods
For further details, see the online supplementary materials (see www.karger.com/doi/10.1159/000448028 for all online suppl. material) [9] ( fig. 1 ).
Results
Out of the 125 patients for whom dapsone treatment was initiated, 26 patients met the inclusion criteria and were appropriate for evaluation after at least 3 consecutive months of treatment. Six of them did not complete 6 months of treatment: 3 patients (12%) due to failure of treatment which occurred during this period, 2 patients (8%) demonstrated remission at 4 months leading to the cessation of dapsone, and 1 patient (4%) suffered from adverse effects attributed to the treatment at 4 months (headaches). The other 99 patients did not meet the inclusion criterion of at least 3 consecutive months of treatment with dapsone due to early adverse effects attributed to the treatment, mainly symptomatic anemia ( fig. 2 ) .
The patients' characteristics are summarized in table 1 . The study group included 15 females (58%) and 11 males (42%). The average age of the patients at PV diagnosis was 43.5 ± 13.1 years, while the average age when initiating dapsone treatment was 44 ± 13.1 years. Only 2 patients (8%) received other adjuvants prior to dapsone: one was treated with methotrexate and the other with azathioprine (Imuran) and intravenous immunoglobulins. Eighteen patients (69%) presented with skin and mucosal involvement, 5 patients (19%) with only skin involvement, and 3 patients (12%) demonstrated only mucosal involvement.
In 15 patients (58%) dapsone treatment was initiated at a dose of 50 mg/day, in 10 patients (38%) at a dose of 100 mg/day, and in 1 patient (4%) at a dose of 75 mg/day. The daily dapsone dosage ranged between 50 and 150 mg/ day, with a median of 62.5 mg/day at 3 months and 75 mg/day at 6 months (an average of 76 ± 31 and 80 ± 33 mg/day, respectively) ( table 2 ). The average length of the dapsone treatment period was 17 months (range: 4-69 months). At the study end point, 7 patients (27%) still used dapsone, while 19 (73%) discontinued the drug: 6 of them (23%) due to remission of their disease. The mean daily dose of prednisone during follow-up is shown in figure 3 . The prednisone daily dose range prior to treatment with dapsone was 0-90 mg/day (mean: 57 ± 24 mg/day). After 3 months of treatment with dapsone as an adjuvant, the prednisone daily dose range was 0-40 mg/day (mean: 11 ± 8 mg/day), and at the last follow-up it was 0-40 mg/day (mean: 12 ± 12 mg/day). This reduction in the daily dose of prednisone is statistically signifi- 2 The mean Hb reduction in the study group was 1.3 mg/dl. 3 Three patients did not complete due to treatment failure (as defined by the consensus statement) after 3 months but before 6 months, 2 due to remission at 4 months, and 1 due to adverse effects at 4 months (headaches). 581 cant (p < 0.001). Overall, at the study end point 11 patients were treated with a dosage of 0-5 mg/day, 6 patients with 6-10 mg/day, 2 patients with 11-15 mg/day, and 7 patients with more than 15 mg/day. Excluding the relapsed patients, 17 patients were treated with a prednisone dosage of less or equivalent to 10 mg/day. Accordingly, considering the prednisone dose as a marker of efficacy, after 3 months of treatment with dapsone an average reduction of 74% in the daily dose of prednisone was demonstrated. After 6 months, a reduction of 86% was shown, and a reduction of 68% was demonstrated at the end point.
According to the consensus observation end points defined by the International Pemphigus Committee, after 3 months of treatment with dapsone 13 patients (50%) were in the consolidation phase, 4 patients (15%) demonstrated partial remission (PR) on minimal therapy, 7 patients (27%) showed complete remission (CR) on minimal therapy, and 2 patients (8%) were defined as treatment failures ( table 2 ). As defined in Materials and Methods, the patients were assessed for the last time either at the termination of dapsone treatment or, for those patients who were still on dapsone treatment, during August 2013. Four (15%) patients were lost to follow-up; thus data about the continuation of dapsone treatment were assessed before August 2013, at their last recorded visit. At the study end points, 11 patients showed CR; 4 of them were still taking dapsone and the other 7 stopped the treatment as a result of either remission (6 patients) or neutropenia (1 patient). Five patients showed PR, 1 of them without treatment. Thus, in total, 16 patients (62%) responded to dapsone. One of the patients who demonstrated CR decided to stop all conventional treatments due to her remission and suffered from a flare-up a few months later. At the final end point, 10 patients (38%) did not respond to the treatment, either due to primary failure or to a relapse. Thirteen patients (50%) stopped dapsone treatment for reasons other than remission: 7 (27%) of them due to relapse, 3 (12%) due to treatment failure, 2 (8%) due to adverse effects (headaches, neutropenia), and 1 (4%) due to pregnancy.
Discussion
Dapsone is an antimicrobial drug with anti-inflammatory properties that is used to treat several skin diseases, including PV, as well as other nondermatological infections and inflammatory diseases [7, 9] . Back in 1976, a review of 107 consecutive cases of pemphigus demonstrated dapsone to be a useful adjuvant to systemic corticosteroids [10] . Since then, dapsone's efficacy as a steroid-sparing agent in the treatment of PV has been documented in several reports [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] . However, the current data are mainly based on small retrospective case series and reports. The present study represents our experience with dapsone in the treatment of PV in 26 patients. Our findings further support dapsone's effectiveness as a steroid-sparing agent in the treatment of PV and emphasize its underutilization in the treatment of this autoimmune blistering disease.
An analysis of current data published in 2009 by Gür-can and Ahmed [6] estimated dapsone's efficacy in the treatment of pemphigus and pemphigoid. In total, 37 patients with PV, in 13 reports, were treated with dapsone. Thirty-two patients (86%) responded to dapsone at a dosage of 50-200 mg/day when used as a monotherapy or as an adjuvant to prednisone/immunosuppressants. Five patients (14%) did not respond. Although the response rate to dapsone in the current report is lower (62%) than that reported in the above review [6] , it still supports the notion that this drug is beneficial as an adjuvant therapy in PV, both in remission induction and as a steroid-sparing agent. This lower response rate may be accounted for by the dosage regimen used in the current study. Contrary to some of the above reports where a maximal dose of 200 mg/day was used [6] , we did not exceed 100 mg/ day of dapsone in the majority of our patients, and the median dose was 75 mg/day. It is noteworthy that in this retrospective series, which is one of the largest reported to date, we evaluated dapsone's efficacy in 26 patients with PV using clinical observation end points defined by the International Pemphigus Committee [9] . The trend of efficacy demonstrated in the current study is similar to that reported in the past for other adjuvants such as mycophenolate mofetil [3] , methotrexate [21] , and others.
Despite its efficacy, only a minority of our patients ( ∼ 20%) could tolerate dapsone for at least a 3-month period. The majority of the patients had to terminate its use prematurely due to adverse effects, mainly symptomatic anemia. It is our experience that a reduction equal to or more than 1.5 g/dl in Hb levels (Hb absolute levels of 10.5 g/dl or less) leads to its termination in most patients. Nevertheless, in most of those patients who initially tolerated the drug, significant adverse effects in the following months were rare. However, even these patients who responded to and tolerated dapsone stopped the drug after a relatively short period. Table 2 summarizes the treatment termination reasons. Therefore, one can conclude that dapsone is effective only in a minority of patients with PV and in most of them for only a rather limited period.
Of note is the high prevalence of G6PD (glucose-6-phosphate dehydrogenase) deficiency (G6PDD) in the Israeli population, as it is in other Mediterranean countries [22] . In the current study patients with G6PDD did not received dapsone in the first place, so the high rate of intolerance to dapsone cannot be attributed to this genetic background. Other enzymes, including multiple hepatic cytochrome P450 isozymes [23] [24] [25] [26] , interact with dapsone and its metabolites, and their level of activity may also account for its toxicity and low tolerance. The Jewish community in Israel is characterized by a relatively homogeneous genetic background, which was found to be of clinical relevance in many situations, and even in PV. Although PV is extremely rare worldwide, it is relatively prevalent in the Jewish population. Recently, the genomic segment on chromosome 8 that spans the ST18 gene was also found to be associated with PV in the Jewish and Egyptian populations. ST18 regulates apoptosis and inflammation, which are relevant in the pathogenesis of PV [27] . This homogeneous genetic background may also play a role in the high rate of intolerance to dapsone reported in this current study ( ∼ 80%), which is higher than reported in other studies.
As a rule, dapsone's use is restricted due to concerns regarding its possible adverse effects, including methemoglobinemia, hemolysis, agranulocytosis, neurotoxicity, toxic hepatitis, renal damage, and the rare hypersensitivity reaction known as 'dapsone syndrome' [7] . Dapsone should not be used for the treatment of PV in patients with G6PDD, as this condition increases the risk of dapsone-induced hemolytic anemia [28, 29] . The risk of adverse effects from dapsone is generally dose dependent [30] . In only 3 of our patients did the dapsone daily dose exceed 100 mg/day.
In general, in the current report, no pharmacological manipulations to increase the patients' tolerance to dapsone were practiced, although such approaches were previously proposed by other authors. Methemoglobinemia is the most common side effect of dapsone [7] . Dapsoneinduced methemoglobinemia occurs as a result of Hb iron trapped in the ferric (Fe 3+ ) state due to the activity of the dapsone toxic metabolite dapsone hydroxylamine. This metabolite is formed due to the N-hydroxylation of dapsone by multiple hepatic cytochrome P450 isozymes, including CYP3A4 [23] [24] [25] [26] . Cimetidine, a histamine H 2 receptor antagonist, can reduce the N-hydroxylation of dapsone [31] . This reduction was demonstrated to result in more than a 25% decrease in methemoglobinemia in patients who received dapsone for the treatment of dermatitis herpetiformis [32] . The coadministration of cimetidine can be considered in selected patients, especially when high doses of dapsone are needed. Another practice aimed at reducing the risk and severity of dapsone's adverse effects is the use of the oral antioxidants vitamins E and C. This practice is based on the assumption that reactive oxygen radicals play a role in dapsone-induced hemolysis [33] . In one study, oral vitamin E supplementation had a partial protective effect against dapsone-induced hemolysis in patients with dermatitis herpetiformis [34] . In order to decrease adverse effects, mainly symptomatic anemia, in some of our patients dapsone was initiated at a low dose (25 mg/day) and was increased gradually (every 3-4 days) up to 100 mg/day according to blood tests results. It is our belief that this approach can increase the patient's tolerance to the drug.
Dapsone's mechanism of action with regard to antibody-mediated diseases is not fully understood. One proposed mechanism is that dapsone inhibits the neutrophil recruitment to IgA and IgG antibodies attached to the basement membrane zone in a dose-dependent manner by blocking the interaction between the Fc portions of these antibodies and the circulating neutrophils [35] . Several other mechanisms regarding dapsone's anti-inflammatory properties have been previously proposed. These include its propensity to interfere with neutrophil chemotactic migration [36, 37] , integrin-mediated adherence [38] , leukocyte myeloperoxidase (MPO) and eosinophil peroxidase (EPO) activity [39] [40] [41] , leukotriene B 4 (LTB 4 ) stimulated inflammation and chemotactic response [42] , 5-lipoxygenase (5-LOX) metabolite production [43] , and the inhibition of lysosomal enzymes [44, 45] . Perhaps the combination of dapsone's various antiinflammatory mechanisms, which mainly target the effector mechanisms of the inflammatory process, may lead to its efficacy in treating a variety of inflammatory dermatoses.
Besides clinical assessment, we also evaluated dapsone efficacy by assessing the reduction in the prednisone dosage. Figure 3 summarizes the mean prednisone dosage before treatment with dapsone, 3 months after the initiation of dapsone treatment, and at the study end point. As seen in the figure, a statistically significant reduction in the mean prednisone dosage is noted with dapsone treatment, although one should keep in mind the possibility that this reduction, at least in part, can be attributed to the natural course of the disease. At the study end point the mean prednisone dosage was similar to that recorded at 3 months.
The choice of which steroid-sparing agent to use in PV patients should take into account multiple aspects of treatment, including the patient's age, comorbidities, previous adjuvants, disease severity, drug adverse effects, its efficacy, and its cost. In this respect, one should be aware that dapsone does not have an immunosuppressive effect. One should also consider that dapsone's US retail daily cost for an adult is only USD 1.30 (USD 474.50/year) [46] . In our opinion, dapsone can be considered as a steroidsparing agent when a low-cost, nonimmunosuppressant drug is desirable, especially in young adult PV patients. If not tolerated soon after the initiation of treatment, then it should be replaced by another drug. In the subgroup of patients in whom it is well tolerated, it is reasonable to expect good efficacy and safety profiles.
Our study has several potential limitations. It is a retrospective study based on a small number of patients. In addition, the lack of a placebo control group is a disadvantage. It is important to mention that PV is a chronic disease characterized by a relapsing and remitting course influenced by many factors. This fact makes it difficult to assess the efficacy of treatments and their long-term effects. In this study, we used standardized disease clinical observation end points defined by the International Pemphigus Committee [9] .
Although dapsone can be a reasonable nonimmunosuppressant steroid-sparing agent for some patients, at least for a limited period of time, and despite the current results as well as previous results indicating dapsone's efficacy in PV, its use is debatable in light of newer drugs, which are efficacious and well tolerated [3, 4] . Dapsone should be an accessible tool in the armamentarium of PV treatments as it does not cause immunosuppression. Thus, it may be used in conjunction with noncytotoxic immunosuppressants (e.g. mycophenolate or rituximab) to increase their efficacy or for the time period until they reach their maximal effect. It can also be considered for young patients and for patients with a limited disease.
In conclusion, the results of the present study, together with previous reports, indicate that dapsone is efficacious and safe in patients with PV in whom it is well tolerated soon after the initiation of treatment. Dapsone has the advantage of being a low-cost, nonimmunosuppressant, steroid-sparing agent. These findings need to be further evaluated in prolonged placebo-controlled or multiple-arm prospective clinical trials.
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